Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04848584 · ClinicalTrials.gov registry record
Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 1
- Enrollment target
NCT04848584: Completed study, sponsored by Pfizer.
NCT04848584 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04848584 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 1 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the vaccine effectiveness of 2 doses of Pfizer-BioNTech BNT162b2 vaccine against COVID-19-associated hospitalization. There will be a large retrospective database study using two parallel study designs: a test-negative case-control design and a retrospective cohort design. VE estimates by various strata and strain type will be conducted.
Primary Outcome
To estimate the effectiveness of 2 doses of BNT162b2 against hospitalization for Acute Respiratory Infection due to SARS-CoV-2 infection
Interventions
- BIOLOGICAL Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine
- BIOLOGICAL BNT162b2 BA.4/5 bivalent
- BIOLOGICAL XBB.1.5-adapted vaccinated
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-05-15 |
| Est. Completion | 2025-04-30 |
What the finished NCT04848584 record still lists
NCT04848584 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine is the first listed.
NCT04848584 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04848584 about?
NCT04848584 is a clinical study titled "Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California". The primary objective of this study is to determine the vaccine effectiveness of 2 doses of Pfizer-BioNTech BNT162b2 vaccine against COVID-19-associated hospitalization. There will be a large retrospective database study using two parallel study designs: a test-negative case-control design and a ret...
What is the current status of trial NCT04848584?
This trial is currently completed. The enrollment target is 1 participants. The study started on 2021-05-15. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT04848584?
The interventions under investigation include: Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine (BIOLOGICAL), BNT162b2 BA.4/5 bivalent (BIOLOGICAL), XBB.1.5-adapted vaccinated (BIOLOGICAL).
Who is sponsoring clinical trial NCT04848584?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI